<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923259</url>
  </required_header>
  <id_info>
    <org_study_id>DNI-P0-653</org_study_id>
    <nct_id>NCT01923259</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition</brief_title>
  <official_title>Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fed State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the relative bioavailability and therefore the bioequivalence of two&#xD;
      different formulations of donepezil after a single oral dose administration under fed&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover&#xD;
      study under fed conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 24, 48 and 72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Donepezil Hydrochloride Tablets, 23 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aricept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AriceptÂ® 23 mg tablet of Eisai Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil Hydrochloride tablets,23 mg</description>
    <arm_group_label>Aricept</arm_group_label>
    <arm_group_label>Donepezil Hydrochloride Tablets, 23 mg</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female volunteer&#xD;
&#xD;
          2. Volunteer aged of at least 18 years but not older than 45 years&#xD;
&#xD;
          3. Volunteer with a body mass index (BMI) greater than or equal to 21 and below 30 kg/m2&#xD;
&#xD;
          4. Volunteer with a body weight greater than or equal to 60 kg.&#xD;
&#xD;
          5. Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes&#xD;
             or less per day for at least 3 months before day 1 of this study. An ex-smoker is&#xD;
             defined as someone who completely stopped smoking for at least 12 months before day 1&#xD;
             of this study.&#xD;
&#xD;
          6. Availability for the entire study period&#xD;
&#xD;
          7. Motivated volunteer and absence of intellectual problems likely to limit the validity&#xD;
             of consent to participate in the study or the compliance with protocol requirements;&#xD;
             ability to cooperate adequately; ability to understand and observe the instructions of&#xD;
             the physician or designee.&#xD;
&#xD;
          8. Clinical laboratory values within the laboratory's stated normal range; if not within&#xD;
             this range, they must be without any clinical significance&#xD;
&#xD;
          9. Have no clinically significant diseases captured in the medical history or evidence of&#xD;
             clinically significant findings on physical examination and/or clinical laboratory&#xD;
             evaluations (hematology, biochemistry, ECG and urinalysis)&#xD;
&#xD;
         10. Willingness to adhere to the protocol requirements as evidenced by the informed&#xD;
             consent form (ICF) duly read, signed and dated by the volunteer&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Seated pulse rate less than 50 bpm at screening&#xD;
&#xD;
          2. Seated blood pressure below 105/60 mmHg at screening&#xD;
&#xD;
          3. Seated blood pressure below 105/60 mmHg before drug administration&#xD;
&#xD;
          4. Females who are pregnant or are lactating&#xD;
&#xD;
          5. Females of childbearing potential who refuse to use an acceptable contraceptive&#xD;
             regimen throughout the entire duration of the study&#xD;
&#xD;
          6. History of significant hypersensitivity to donepezil, piperidine derivatives,&#xD;
             scopolamine, or any related products (including excipients of the formulations) as&#xD;
             well as severe hypersensitivity reactions (like angioedema) to any drugs&#xD;
&#xD;
          7. Presence of significant gastrointestinal, liver or kidney disease, or any other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs or known to potentiate or predispose to undesired effects&#xD;
&#xD;
          8. History of significant gastrointestinal, liver or kidney disease that may affect drug&#xD;
             bioavailability&#xD;
&#xD;
          9. Presence of significant cardiovascular, pulmonary, hematologic, neurological,&#xD;
             psychiatric, endocrine, immunologic or dermatologic disease&#xD;
&#xD;
         10. Suicidal tendency, history of or disposition to seizures, state of&#xD;
             confusion,clinically relevant psychiatric diseases&#xD;
&#xD;
         11. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 200 msec, QRS &gt;110 msec&#xD;
             and QTc &gt; 440 msec) on the screening ECG or other clinically significant ECG&#xD;
             abnormalities.&#xD;
&#xD;
         12. Use of ASA or NSAIDs (or any product containing ASA or NSAIDs) in the previous 7 days&#xD;
             before day 1 of this study&#xD;
&#xD;
         13. Use of diphenhydramine in the previous 10 hours before day 1 of this study&#xD;
&#xD;
         14. Known presence of rare hereditary problems of galactose and /or lactose intolerance&#xD;
&#xD;
         15. Known presence of glaucoma or a predisposition to angle-closure glaucoma&#xD;
&#xD;
         16. Maintenance therapy with any drug, or significant history of drug dependency or&#xD;
             alcohol abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol, acute or&#xD;
             chronic)&#xD;
&#xD;
         17. Any clinically significant illness in the previous 28 days before day 1 of this study&#xD;
&#xD;
         18. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450&#xD;
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,&#xD;
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP&#xD;
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and&#xD;
             St John's Wort), in the previous 28 days before day 1 of this study&#xD;
&#xD;
         19. Any history of tuberculosis and/or prophylaxis for tuberculosis&#xD;
&#xD;
         20. Positive urine screening of alcohol and/or drugs of abuse&#xD;
&#xD;
         21. Positive results to HIV, HBsAg or anti-HCV tests&#xD;
&#xD;
         22. Females who are pregnant according to a positive serum pregnancy test&#xD;
&#xD;
         23. Volunteers who took an Investigational Product (in another clinical trial) or donated&#xD;
             50 mL or more of blood in the previous 28 days before day 1 of this study.&#xD;
&#xD;
         24. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical&#xD;
             studies, etc.) in the previous 56 days before day 1 of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mount Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

